Organon Canada extends the Remind Me Today! reminder program
TORONTO, Oct. 29 /PRNewswire/ - Organon Canada continues to benefit from its Remind Me Today! reminder program for its Linessa(R) and Nuvaring(R) contraceptive brands. Women are delighted by the free telephone-based program that helps them remember their contraceptives and Organon Canada is receiving excellent feedback from their sales reps, physicians and patients.
Organon Canada initiated the Remind Me Today! telephone-based reminder program in February 2007 in an effort to improve brand recognition and offer women a valuable, cost-effective and lifestyle-friendly reminder solution. The number of registrations continues to increase every month, exceeding expectations with a retention rate of higher than 91%.
A closer look at the problem of medication non-compliance reveals that unfilled and unused prescriptions are responsible for over 125,000 deaths in the U.S. every year. (2004 Disease Management Directory and Guidebook; Pharma Futures Inc.)
MEMOTEXT(R) adherence programs are a very cost effective way to improve compliance. Depending on the condition and the patient demographics, telephone-based reminder programs have been shown to increase compliance between 8% and 40%. The MEMOTEXT(R) personalized adherence solution sends automated interactive daily text or voice call reminders to a patient's home, office or cellular phone.
"Medication non-compliance is a serious issue for the healthcare industry," explains Amos Adler, President of Enterprising Vision Inc., provider of MEMOTEXT(R). "Research shows that dropout rates for anti-hypertensive and cholesterol-lowering drugs can be as high as 50%. Billions of dollars are being lost across the board from government to pharmaceutical companies - dollars that are directly attributable to healthcare-related non-compliance."
Organon Canada, makers of the Linessa(R) and NuvaRing(R) contraceptives, understands the important relationship between successful healthcare outcomes and the use of communications technology. "The Remind Me Today! program offers women a highly effective lifestyle tool that takes the stress out of remembering," says Meena Bhogal, Sr. Product Manager. "By offering our patients this unique value-added service we are creating a very positive brand experience that truly differentiates us in the marketplace."
Treating patients as partners in their own healthcare is key. "Patients want to be educated and they want support with approaches that suit their lifestyles. We know that interactive communications technology can bridge this gap." says Adler.
Continuing its commitment to high quality products for women, Organon Canada has renewed its contract with Toronto's MEMOTEXT(R) to provide women with the custom designed Remind Me Today! program until 2009 with free reminder messages until 2010.
Organon creates, manufactures and markets innovative prescription medicines that improve the health and quality of human life. Through a combination of innovation and business partnerships, Organon seeks to leverage its position as a leading biopharmaceutical company in each of its core therapeutic fields: fertility, gynecology and selected areas of anesthesia. It has extensive expertise in neuroscience and a rich and focused R&D program. Research areas also include immunology and specific areas of oncology. Organon products are distributed in over 100 countries worldwide, of which more than 50 have an Organon subsidiary. Organon is the human healthcare business unit of Akzo Nobel.
Safe Harbor Statement
This press release may contain forward-looking statements. These forward-looking statements, addressing without limitation such key issues as growth strategy, future financial results, market positions, and product development, are based on current expectations of future events and circumstances and can be identified by the fact that they use words such as "will", "anticipate", "estimate", "expect", "project", "intend", "plan", "believe", "target", "forecast", and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or business prospects.
Such forward-looking statements should be carefully considered, and it should be understood that many factors could cause forecasted and actual results to differ from these forward-looking statements. Organon BioSciences undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or circumstances, or otherwise.
The forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Organon BioSciences' business, particularly but without limitation including general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment.
Copyright©2007 PR Newswire.
All rights reserved